Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
- PMID: 12409965
- DOI: 10.1097/00004872-200211000-00026
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
Abstract
Objective: To investigate the hypothesis that weight reduction with orlistat plus mild caloric restriction leads to better blood pressure control than diet alone in obese individuals with inadequately controlled hypertension. DESIGN This was a 1-year, prospective, randomized, double-blind, placebo-controlled, multicenter trial of orlistat plus diet versus placebo plus diet in obese hypertensives.
Interventions: Participants were randomized to receive either orlistat or placebo; all received a 600 kcal deficient diet with no more than 30% of calories from fat. Weight and blood pressure, lipid levels and fasting glucose and insulin levels were followed.
Main outcome measures: Patients on orlistat experienced greater weight loss (-5.4 +/- 6.4 versus -2.7 +/- 6.4 kg, P< 0.001) and greater reduction in body mass index (-1.9 +/- 2.3 versus -0.9 +/- 2.2 kg/m2, P<0.001). Target weight loss, defined as > or= 5% body weight (BW), was obtained in more orlistat-treated patients than in the placebo group (46 versus 23%, P<0.001). Diastolic BP decreased more in orlistat-treated patients than in the placebo group (-11.4 +/- 8.3 versus -9.2 +/- 8.4 mmHg, P = 0.002). A greater percentage of orlistat-treated patients reached goal diastolic blood pressure (BP), defined as final diastolic BP< 90 mmHg or a reduction of at least 10 mmHg (67 versus 53%, P< 0.001). The orlistat-treated group had significantly greater reductions in total cholesterol ( P<0.001), low-density lipoprotein cholesterol (P = 0.001) and non-high-density lipoprotein cholesterol (P< 0.005) and target 30% cardiovascular risk reduction was obtained in more orlistat-treated patients (36.1 versus 24.0%, P< 0.04).
Conclusion: A weight-loss program with orlistat is more effective than diet alone to lower blood pressure and results in greater cardiovascular risk reduction.
Similar articles
-
Long-term effects of weight-reducing drugs in hypertensive patients.Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007654. doi: 10.1002/14651858.CD007654.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2016 Mar 02;3:CD007654. doi: 10.1002/14651858.CD007654.pub4. PMID: 23543553 Updated. Review.
-
Long-term effects of weight-reducing drugs in hypertensive patients.Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007654. doi: 10.1002/14651858.CD007654.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007654. doi: 10.1002/14651858.CD007654.pub3. PMID: 19588440 Updated. Review.
-
[Pharmacological therapy of obesity].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. G Ital Cardiol (Rome). 2008. PMID: 18773755 Italian.
-
Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.J Hypertens. 2003 Nov;21(11):2159-65. doi: 10.1097/00004872-200311000-00026. J Hypertens. 2003. PMID: 14597860 Clinical Trial.
-
Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.Clin Ther. 2003 Apr;25(4):1107-22. doi: 10.1016/s0149-2918(03)80070-x. Clin Ther. 2003. PMID: 12809960 Clinical Trial.
Cited by
-
Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis.Diabetes Metab Syndr Obes. 2022 Dec 17;15:3961-3987. doi: 10.2147/DMSO.S392952. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 36569429 Free PMC article. Review.
-
Does weight management research for adults with severe obesity represent them? Analysis of systematic review data.BMJ Open. 2022 May 31;12(5):e054459. doi: 10.1136/bmjopen-2021-054459. BMJ Open. 2022. PMID: 35641006 Free PMC article.
-
Amentoflavone-Enriched Selaginella rossii Warb. Suppresses Body Weight and Hyperglycemia by Inhibiting Intestinal Lipid Absorption in Mice Fed a High-Fat Diet.Life (Basel). 2022 Mar 24;12(4):472. doi: 10.3390/life12040472. Life (Basel). 2022. PMID: 35454963 Free PMC article.
-
The best drug supplement for obesity treatment: a systematic review and network meta-analysis.Diabetol Metab Syndr. 2021 Oct 18;13(1):110. doi: 10.1186/s13098-021-00733-5. Diabetol Metab Syndr. 2021. Retraction in: Diabetol Metab Syndr. 2023 Apr 17;15(1):74. doi: 10.1186/s13098-023-01048-3. PMID: 34663429 Free PMC article. Retracted.
-
Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis.Eur J Clin Pharmacol. 2021 Nov;77(11):1611-1621. doi: 10.1007/s00228-021-03160-7. Epub 2021 May 27. Eur J Clin Pharmacol. 2021. PMID: 34043049
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical